Clinical Long-Term Evaluation of Approved and Investigational Contact Lenses

Inclusion Criteria: * The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. * The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. * The subject must be at least 18 years of age. * The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 in each eye. * The subject's refractive cylinder must be ≤ 1.00 Diopters (D) in each eye. * The subject must have best corrected visual acuity of 20/25 or better in each eye. * The subject should own a wearable pair of spectacles and bring to initial visit. * The subject must be an adapted frequent replacement daily wear spherical silicone hydrogel soft contact lens wearer in both eyes. * The subject must have normal eyes (i.e., no ocular medications or infections of any type). * The subject must have enrolled and completed all visits in clinical study (NCT02515994). Exclusion Criteria: * Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued). * Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g., hepatitis, tuberculosis). * Use of any of the following medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g., Accutane), oral tetracyclines, topical scopolamine, oral phenothiazines (e.g. Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), oral and ophthalmic Beta-adrenergic blockers (e.g., Propranolol, Timolol, and Practolol), systemic steroids, and any prescribed or OTC ocular medication. * Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion. * Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), etc.) * Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear. * Any known hypersensitivity or allergic reaction to Opti-Free® PureMoist® multipurpose care solution or Eye-Cept rewetting drop solution * Any ocular infection, allergy or clinically significant ocular disease (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca, ocular hypertension), or ocular conditions (e.g. strabismus), which might interfere with the study. * Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. * Daily disposables, extended wear, monovision or multi-focal contact lens correction. * History of binocular vision abnormality or strabismus. * Employee or relative of employees of sponsor or investigational clinic (e.g., Investigator, Coordinator, Technician)